Revolution Medicines priced a $2 billion combined stock and debt offering, the largest public financing in the US biotech space since the Covid-era, according to the company’s report. The raise comes after Phase 3 data for its experimental pancreatic cancer drug daraxonrasib showed a doubling of median overall survival versus chemotherapy. The capital market reaction underscores how clinical success—rather than broader sentiment—continues to drive access to large follow-on funding for late-stage developers. It also sets up near-term runway for additional regulatory and manufacturing steps tied to potential accelerated review paths.